In an era where the battle against obesity is relentless, a groundbreaking clinical trial is set to investigate the dual treatment of the diabetes drug Mounjaro alongside an experimental muscle loss drug, azelaprag. The focus of this trial isn’t just about shedding weight, but crucially, about maintaining muscle mass – a concern often overlooked in weight loss studies. The announcement on Thursday revealed that the joint venture between BioAge Labs and Eli Lilly’s development arm, Chorus, seeks to explore how these medications may positively impact body composition.
Azelaprag, designed to mimic the activity of apelin – a substance naturally released in the body post-exercise – holds promise in preventing muscle atrophy and promoting muscle regeneration. The drug has exhibited significant potential in averting muscle loss, particularly among older adults, as indicated in BioAge’s previous clinical trials. Meanwhile, Mounjaro, classified as a glucagon-like peptide-1 (GLP-1) receptor agonist primarily used for diabetes treatment, is also gaining attention for its potential in weight loss, akin to the popular drugs Ozempic and Wegovy.
The forthcoming trial is poised to scrutinize how combining both azelaprag and Mounjaro might impact weight loss and body composition in obese individuals. Early preclinical studies on obese mice have shown promising signs – an increase in total weight loss with a normalized body composition and reduced glucose levels without a significant decrease in calorie intake. Kristen Fortney, BioAge’s CEO, emphasized the potential of this combined approach, believing it could foster healthier weight loss methods.
CDC reports that 41.9% of adults aged 60 and above grapple with obesity
However, this trial arrives on the heels of concerns raised by previous studies, notably involving semaglutide, an active ingredient in Ozempic and Wegovy, which pointed to potential lean muscle loss in participants. This is a critical factor given that the average age of participants was 52, underlining the need to understand the nuances of weight loss in relation to muscle preservation.
These developments come at a time when obesity continues to prevail among older adults in the United States. The Centers for Disease Control and Prevention reports that 41.9% of adults aged 60 and above grapple with obesity. This ongoing battle against weight-related health issues intensifies the urgency for more comprehensive weight loss solutions that don’t compromise muscle mass.
As the trial is slated to commence in mid-2024, the anticipation is high for the potential insights that might emerge from this innovative approach. The focus on not just shedding weight but retaining muscle mass signifies a significant shift in the landscape of weight loss strategies, offering hope for more holistic and effective solutions in the fight against obesity.
Medically directed weight loss program
When it comes to achieving sustainable weight loss and overall well-being, a medically directed weight loss program stands out as a superior option. Unlike fad diets or quick-fix solutions, a medically supervised program takes a holistic and evidence-based approach to address individual health needs.
These programs are tailored to the specific requirements of each participant, considering factors like age, medical history, lifestyle, and underlying health conditions. The guidance of trained healthcare professionals ensures that weight loss is achieved safely and with a focus on long-term results. Medical supervision also provides a comprehensive understanding of the metabolic and physiological aspects of weight management, making it possible to create a customized plan that promotes not only weight loss but also improved health, reduced risks of obesity-related conditions, and sustainable lifestyle changes.
In this way, a medically directed weight loss program offers a well-rounded, scientifically grounded, and effective approach to achieving and maintaining a healthy weight.
Weight Loss
Get access to GLP-1 medication and 1:1 support to meet your weight loss goals.
References
Drug Trial Snapshot: Ozempic - Referenced from: https://fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-ozempic
Once-Weekly Semaglutide in Adults with Overweight or Obesity - Referenced from: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
BioAge Trial - Referenced from: https://www.businesswire.com/news/home/20221205005201/en/BioAge-Announces-Positive-Topline-Results-for-BGE-105-in-Phase-1b-Clinical-Trial-Evaluating-Muscle-Atrophy-in-Older-Volunteers-at-Bed-Rest
